Antimicrobial Agents and Chemotherapy, March 2000, p. 794-797, Vol. 44, No. 3
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
University of Rochester School of Medicine and Dentistry, Rochester, New York1; Stanford University, Palo Alto, California2; Harvard School of Public Health, Boston, Massachusetts3; University of Miami, Miami, Florida4; Pharmacia and Upjohn, Kalamazoo, Michigan5; and Ohio State University, Columbus, Ohio6
Received 23 August 1999/Returned for modification 4 November 1999/Accepted 29 November 1999
The development of human immunodeficiency virus type 1 resistance to delavirdine (DLV) was studied in subjects receiving DLV monotherapy. Phenotypic resistance developed in 28 of 30 subjects within 8 weeks. K103N and Y181C, which confer nonnucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance, were the predominant reverse transcriptase mutations. P236L, which confers DLV resistance but hypersensitivity to other NNRTIs, developed in <10% of isolates.
This article has been cited by other articles:
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |